Glecaprevir/pibrentasvir

Drug Profile

Glecaprevir/pibrentasvir

Alternative Names: 2DAA; ABT-493/ABT-530

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator AbbVie
  • Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hepatitis C

Most Recent Events

  • 25 Apr 2017 Efficacy and adverse event data from the phase III ENDURANCE trial in Hepatitis C released by Abbvie
  • 25 Apr 2017 AbbVie initiates an expanded access to glecaprevir/pibrentasvir for Hepatitis C (NCT03123965)
  • 21 Apr 2017 Kirby Institute plans the SMART-C phase III trial for Hepatitis C (Treatment naive) in Australia, Canada and New Zealand (NCT03117569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top